CJC-1295 (with DAC) vs GHRP-2: side-by-side comparison
CJC-1295 DAC · CJC-1295 with DAC · DAC:GRF
A synthetic analogue of growth hormone-releasing hormone (GHRH), developed by ConjuChem as a modified GRF(1-29)/sermorelin bearing a drug affinity complex (DAC). The DAC: a maleimidopropionyl-lysine group added at the C-terminus, bonds to albumin in the bloodstream, protecting the peptide from degradation and stretching its half-life to an estimated 6-8 days. A single dose can raise GH and IGF-1 for days. This long action is the key contrast with CJC-1295 "no DAC" (Modified GRF 1-29), whose ~30-minute half-life preserves natural pulses.
Pralmorelin · Growth Hormone Releasing Peptide 2 · KP-102
A synthetic hexapeptide ghrelin mimetic that stimulates growth hormone release by binding to the growth hormone secretagogue receptor (GHS-R1a). More potent than GHRP-6 with fewer side effects, particularly less appetite stimulation. Often combined with GHRH peptides (Mod GRF/CJC-1295) for synergistic GH release.
4 / 10 natty scale / 4
Same lane
Both sit in the same class and are run for recovery, performance, longevity. This is a like-for-like comparison: read the gaps as real trade-offs.
The tape
Core ratings
The same three rulers every entry on the site is scored with, read head to head.
Natty scale
1 natural · 10 heavy
Effectiveness
Documented effect · of 5
Side-effect severity
Documented burden · of 5
Cost side
Body-load fingerprint
Where each one actually lands its strain, on the calculator's thirteen channels. Tap a row for what it means and which labs track it.
Cardiometabolic
Hormonal
Injection & site care
Bars show strain at each one's typical protocol, not your dose. ≈ marks values inferred from side-effect data or category rather than hand-graded. For your numbers, run the calculator.
Logistics
The vitals
Benefit side
What each is for
Shared goals carry both dots; a goal with one dot belongs to that side alone.
Run for
Documented upside
- Very long half-life (~6-8 days) from a single injection
- Sustained GH and IGF-1 elevation (Teichman 2006)
- Stimulates endogenous GH rather than replacing it
- Far fewer injections than no-DAC GHRH analogues
- Does not suppress the testosterone axis - no PCT required
Run for
Documented upside
- More potent GH release than GHRP-6 (lower ED50)
- Minimal appetite stimulation compared to GHRP-6
- Lower cortisol and prolactin elevation than GHRP-6
- Signals via the GHS-R1a / PLC-PKC pathway, complementary and synergistic with GHRH analogs
- Low desensitization risk at standard doses
The downsides
Side effects, aligned
Each entry's documented side effects, sorted onto the same body systems so the gaps and the overlaps are visible. Tap any effect for the detail.
None documented
None documented
The exit
Hormonal fallout & recovery
What each does to your own hormone axis while on, and what leaving it costs.
CJC-1295 (with DAC)
Stimulates endogenous GH via the GHRH receptor; does not affect the HPT axis. No PCT required.
GHRP-2
Does not affect HPT axis. No PCT required.
Read-out
How they separate
- 01
Enhancement
They land at almost the same point on the natty scale (4/10 vs 4/10): a similar distance beyond natural.
- 02
Body load
The widest gap at typical protocols is prolactin (GHRP-2 3.2/10 vs 0/10).
- 03
Coming off
Neither requires PCT: both leave the natural testosterone axis running.
- 04
Logistics
typical runs are 8-12 weeks vs 4-12 weeks.
- 05
Tested athletes
Both are WADA-prohibited: neither belongs anywhere near tested competition.
Generated from each entry's data file. Descriptive, not a recommendation; nothing here is medical advice.